Welcome to the Settlement website for In re Salix Pharmaceuticals Ltd., pending in the United States District Court for the Southern District of New York (the “Action”).
The Court-appointed Lead Plaintiff, the Pentwater Funds, on behalf of itself and the other members of the Settlement Class (defined below), has reached a settlement of this Action with defendant Salix Pharmaceuticals, Ltd. (“Salix”) and defendants Carolyn J. Logan and Adam C. Derbyshire for $210,000,000 in cash that resolves all claims in the Action (the “Settlement”).
Following a hearing on July 28, 2017, the Court entered a Judgment approving the Settlement as fair, reasonable and adequate, and entered orders approving the Plan of Allocation for the proceeds of the Settlement, and approving Lead Counsel’s motion for attorneys’ fees and reimbursement of expenses.
If you are a member of the Settlement Class, your rights will be affected and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
all persons or entities who purchased or otherwise acquired publicly traded Salix common stock or publicly traded call options on Salix common stock, or sold publicly traded put options on Salix common stock, during the period from November 8, 2013 through November 6, 2014, inclusive (the “Class Period”), and were damaged thereby, except for certain persons and entities who are excluded from the Settlement Class by definition (see paragraph 21 of the Notice).
The deadline for submission of Claim Forms was August 9, 2017. Payments to eligible claimants will be made only after the completion of all claims processing. Please be patient, as this process will take some time to complete.
IMPORTANT DATES AND DEADLINES
|August 9, 2017||Claim Filing Deadline. The deadline for submission of Claim Forms was August 9, 2017.|